GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lakefront Biotherapeutics LKFT · USD

US listing · 🇺🇸 United States

Compare

33.52

+0.21%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$1.29bn

FY2022FY2025

Net income

$371.5m

FY2022FY2025

Free cash flow

−$314.1m

FY2022FY2025

Shareholders' equity

$3.75bn

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue$1.29bn$319.1m$277.5m$279.3m
Gross profit$1.25bn$278.7m$277.5m$279.3m
Research and development$531.8m$388.3m$279.3m$312.3m
Operating income$580.4m−$218.0m−$102.2m−$151.7m
Net income$371.5m$85.8m$245.1m−$252.3m
Diluted earnings per share5.641.303.71-3.82

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets$3.94bn$4.79bn$5.04bn$5.48bn
Cash and short-term investments$3.47bn———
Total liabilities$197.5m$1.43bn$1.81bn$2.56bn
Debt$2.0m———
Shareholders' equity$3.75bn$3.35bn$3.24bn$2.92bn
Shares outstanding66m66m66m66m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations−$298.0m−$370.5m−$469.9m−$579.4m
Capital spending−$16.0m−$95.0m−$22.3m−$42.8m
Free cash flow−$314.1m−$465.5m−$492.3m−$622.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025
Revenue$14.0m$7.5m$1.04bn$82.4m$75.6m$86.8m
Gross profit−$26.1m$1.9m$1.04bn$69.8m$70.1m$70.9m
Operating income−$50.4m−$73.7m$878.4m−$48.2m−$66.0m−$183.7m
Net income$2.4m$16.8m$905.4m−$234.0m−$122.4m−$177.6m
Diluted earnings per share0.030.2413.74-3.55-1.86-2.69
Cash from operations—−$95.0m−$54.0m−$72.0m−$125.0m−$44.0m
Capital spending——−$1.0m−$3.0m−$4.0m−$6.0m
Free cash flow——−$55.0m−$75.0m−$129.0m−$50.0m
Total assets$3.88bn$3.90bn$3.94bn$4.07bn$4.42bn$4.66bn
Cash and short-term investments$2.59bn$3.45bn$3.47bn$3.53bn$3.58bn—
Debt$1.8m$1.8m$2.0m$2.0m$2.8m—
Shareholders' equity$3.77bn$3.77bn$3.75bn$2.83bn$3.06bn$3.18bn

Financial ratios

Data as of 31 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin97.3%87.4%100.0%100.0%-36.7%—
Operating margin27.3%-0.8%3.1%-25.6%-73.2%—
Net margin28.9%26.9%88.3%-90.4%-44.0%—
Return on equity9.9%2.6%7.6%-8.6%——
Return on assets9.4%1.8%4.9%-4.6%——
Free cash flow yield-11.5%-24732.8%-18.2%22300.8%——
Revenue growth303.5%15.0%-0.6%2.9%——
Earnings growth333.1%-65.0%-197.1%111.2%——
Current ratio20.15x9.97x9.02x8.11x——
Debt to equity0.00x—————
Equity ratio95.0%70.0%64.2%53.4%——
Interest coverage136.71x-2.39x4.18x-6.74x-19.66x—
R&D as a share of sales41.3%121.7%100.7%111.8%136.7%—
Buybacks as a share of market value-221030.9%100.0%102480.4%100.1%-0.9%-8.3%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue68.6%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin95.3%96.5%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings5.821.210.9-11.6
Price to sales1.75.79.810.9

Market value over time

31 Jan 2023 to 30 Oct 2026, in USD

$2.92bn$2.26bn

Share price return

Finished calendar years

202520242023202220212020
Return19%-33%-0%-26%-44%-54%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.